• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥瑞珠单抗治疗复发缓解型多发性硬化症后发生急性胰腺炎。

Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.

作者信息

Adamec Ivan, Reiner Željko, Pećin Ivan, Šućur Nediljko, Godan Hauptman Ana, Barun Barbara, Gabelić Tereza, Habek Mario

机构信息

University Hospital Center Zagreb Department of Neurology, Referral Center for Autonomic Nervous System Disorders, Zagreb, Croatia.

University Hospital Center Zagreb Department of Internal Medicine, Division of Metabolic Diseases, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.

出版信息

Mult Scler Relat Disord. 2020 Oct;45:102381. doi: 10.1016/j.msard.2020.102381. Epub 2020 Jul 7.

DOI:10.1016/j.msard.2020.102381
PMID:32653735
Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody used in the treatment of relapsing remitting and primary progressive multiple sclerosis. The main side effects are infusion-related with long term administration raising the risk of infections. During randomized controlled trials five cases of pancreatitis have been reported. We present a case of a patient with no risk factors for pancreatitis who after administration developed acute pancreatitis albeit with a good recovery.

摘要

奥瑞珠单抗是一种用于治疗复发缓解型和原发性进展型多发性硬化症的抗CD20单克隆抗体。主要副作用与输液有关,长期使用会增加感染风险。在随机对照试验期间,报告了5例胰腺炎病例。我们报告一例无胰腺炎危险因素的患者,在使用奥瑞珠单抗后发生了急性胰腺炎,不过恢复良好。

相似文献

1
Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.奥瑞珠单抗治疗复发缓解型多发性硬化症后发生急性胰腺炎。
Mult Scler Relat Disord. 2020 Oct;45:102381. doi: 10.1016/j.msard.2020.102381. Epub 2020 Jul 7.
2
Ocrelizumab for the treatment of multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.
3
Viral pericarditis following ocrelizumab in a multiple sclerosis patient.奥瑞珠单抗治疗多发性硬化症患者后并发病毒性心包炎。
Neurol Sci. 2023 Aug;44(8):2947-2949. doi: 10.1007/s10072-023-06782-0. Epub 2023 Apr 25.
4
Dengue fever in a multiple sclerosis patient taking Ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者并发登革热。
Mult Scler. 2021 Nov;27(13):2116-2118. doi: 10.1177/13524585211030214. Epub 2021 Aug 27.
5
Two cases of meningitis associated with ocrelizumab therapy.两例与奥瑞珠单抗治疗相关的脑膜炎。
Mult Scler Relat Disord. 2020 Feb;38:101866. doi: 10.1016/j.msard.2019.101866. Epub 2019 Nov 27.
6
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.奥瑞珠单抗输注时间缩短:复发缓解型多发性硬化症患者随机双盲ENSEMBLE PLUS子研究结果
Mult Scler Relat Disord. 2020 Nov;46:102492. doi: 10.1016/j.msard.2020.102492. Epub 2020 Sep 24.
7
Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis.选定复发缓解型多发性硬化症患者使用半剂量奥瑞珠单抗治疗。
Acta Neurol Belg. 2024 Feb;124(1):303-306. doi: 10.1007/s13760-023-02303-0. Epub 2023 Jun 10.
8
Ocrelizumab: A Review in Multiple Sclerosis.奥瑞珠单抗:多发性硬化症的治疗药物。
Drugs. 2022 Feb;82(3):323-334. doi: 10.1007/s40265-022-01672-9. Epub 2022 Feb 22.
9
Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.奥瑞珠单抗治疗复发缓解型多发性硬化后出现银屑病样皮炎:病例报告及文献复习。
Mult Scler. 2024 Jun;30(7):893-897. doi: 10.1177/13524585241232277. Epub 2024 Feb 22.
10
Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.奥瑞珠单抗:一种用于治疗复发缓解型和原发性进展型多发性硬化症的新型 B 细胞疗法。
Ann Pharmacother. 2018 May;52(5):473-483. doi: 10.1177/1060028017747635. Epub 2017 Dec 12.

引用本文的文献

1
Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised).药物性急性胰腺炎:一种基于证据的分类(修订版)。
Clin Transl Gastroenterol. 2023 Aug 1;14(8):e00621. doi: 10.14309/ctg.0000000000000621.
2
Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab.多发性硬化症患者在使用特立氟胺和奥瑞珠单抗治疗后发生局灶节段性肾小球硬化。
J Nephrol. 2023 Apr;36(3):659-661. doi: 10.1007/s40620-022-01504-9. Epub 2022 Nov 21.
3
Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
单抗(阿仑单抗和奥瑞珠单抗)治疗多发性硬化症的产品评价。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4345-4362. doi: 10.1080/21645515.2021.1969850. Epub 2021 Oct 20.